A mini-review distinguishes immediate withdrawal management from longer-lasting neurocognitive changes during abstinence.
The review discusses regional glucocorticoid dysregulation and animal evidence for receptor-targeted interventions. It contrasts the role of diazepam in early withdrawal with experimental findings about persistent cognitive and endocrine abnormalities. Baclofen and glucocorticoid-receptor approaches are discussed as research directions.
Much of the cited work is preclinical, and memory effects can depend on dose and experimental conditions. The review does not provide a new randomized human comparison proving that another drug should replace benzodiazepines for acute withdrawal. Preventing seizures, reducing anxiety, restoring cognition, and changing regional hormone signaling are separate endpoints. The paper is useful for explaining why control of acute symptoms does not demonstrate resolution of every long-term effect of alcohol exposure or withdrawal.
Original analysis of the supplied journal article, identified as PMC6759466.